glp-1 cardiovascular outcomes trial august 2025 Bridging the gap between GLP1-receptor agonists and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology Kidney and Cardiovascular Outcomes Among

For most patients, GLP-1 medications are generally safe and well-tolerated, but like any medication, they can have side effects such as nausea, vomiting, diarrhea, or constipation

[DOI] [PMC free article] [PubMed] [Google Scholar] 89.Karhunen V, Daghlas I, Zuber V, Vujkovic M, Olsen AK, Knudsen LB, Haynes WG, Howson JMM, Gill D

LDL cholesterol decreased by approximately 5-7 mg/dL, while HDL cholesterol showed modest increases

Wegovy addresses the physical sensation of fullnessthe ability to stop eating sooner and stay satisfied longer

Finally, none of the multi-agonists at lower doses, nor metformin, had a beneficial effect on ovarian cyclicity or any other gonadal parameter, such as ovarian and uterus weights and circulating LH levels (Suppl

and this was required for the study, patients are U.S